- VIVUS and Metuchen Pharmaceuticals Announce License Agreement for Commercial Rights to STENDRA
- VIVUS Extends Return Date of STENDRA Commercial Rights
- VIVUS Reports 2016 Second Quarter Financial Results
- VIVUS Files Lawsuit Against Hetero for Infringement of Stendra Patents
- VIVUS Announces Date of 2016 Second Quarter Business Update and Financial Results Teleconference
Latest EventsThere are currently no upcoming events
A Growing Pipeline
VIVUS is developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health.